Advances in CAR T cell therapy for non-small cell lung cancer Review
| Authors: | Ma, H. Y.; Das, J.; Prendergast, C.; De Jong, D.; Braumuller, B.; Paily, J.; Huang, S.; Liou, C.; Giarratana, A.; Hosseini, M.; Yeh, R.; Capaccione, K. M. |
| Review Title: | Advances in CAR T cell therapy for non-small cell lung cancer |
| Abstract: | Since its first approval by the FDA in 2017, tremendous progress has been made in chimeric antigen receptor (CAR) T cell therapy, the adoptive transfer of engineered, CAR-expressing T lymphocyte. CAR T cells are all composed of three main elements: an extracellular antigen-binding domain, an intracellular signaling domain responsible for T cell activation, and a hinge that joins these two domains. Continuous improvement has been made in CARs, now in their fifth generation, particularly in the intracellular signaling domain responsible for T cell activation. CAR T cell therapy has revolutionized the treatment of hematologic malignancies. Nonetheless, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success. Here we review the challenges in achieving effective CAR T cell therapy in solid tumors, and emerging CAR T cells that have shown great promise for non-small cell lung cancer (NSCLC). A growing number of clinical trials have been conducted to study the effect of CAR T cell therapy on NSCLC, targeting different types of surface antigens. They include epidermal growth factor receptor (EGFR), mesothelin (MSLN), prostate stem cell antigen (PSCA), and mucin 1 (MUC1). Potential new targets such as erythropoietin-producing hepatocellular carcinoma A2 (EphA2), tissue factor (TF), and protein tyrosine kinase 7 (PTK7) are currently under investigation in clinical trials. The challenges in developing CAR T for NSCLC therapy and other approaches for enhancing CAR T efficacy are discussed. Finally, we provide our perspective on imaging CAR T cell action by reviewing the two main radionuclide-based CAR T cell imaging techniques, the direct labeling of CAR T cells or indirect labeling via a reporter gene. © 2023 by the authors. |
| Keywords: | treatment response; review; erlotinib; liver cell carcinoma; solid tumor; pancreas cancer; colorectal cancer; ipilimumab; cancer immunotherapy; ovary cancer; breast cancer; epidermal growth factor receptor; lung cancer; food and drug administration; protein tyrosine kinase; renal cell carcinoma; prostate cancer; hematologic malignancy; immunotherapy; neuroblastoma; glioblastoma; gefitinib; reporter gene; mesothelioma; chimeric antigen receptor; cell therapy; adoptive transfer; imaging; stomach cancer; mucin 1; trastuzumab; antigen binding; pemetrexed; non-small cell lung cancer; prostate stem cell antigen; t lymphocyte activation; solid tumors; mesothelin; intracellular signaling; non small cell lung cancer; nsclc; tumor microenvironment; clinical trial (topic); tocilizumab; afatinib; dacomitinib; nivolumab; human; ceritinib; pembrolizumab; alectinib; brigatinib; osimertinib; atezolizumab; avelumab; lorlatinib; chimeric antigen receptor t-cell immunotherapy; car t cell therapy; checkpoint inhibitor immunotherapy |
| Journal Title: | Current Issues in Molecular Biology |
| Volume: | 45 |
| Issue: | 11 |
| ISSN: | 1467-3037 |
| Publisher: | Horizon Scientific Press |
| Date Published: | 2023-11-01 |
| Start Page: | 9019 |
| End Page: | 9038 |
| Language: | English |
| DOI: | 10.3390/cimb45110566 |
| PROVIDER: | scopus |
| PMCID: | PMC10670348 |
| PUBMED: | 37998743 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work